Annexon, Inc. (ANNX)
| Market Cap | 154.64M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -139.64M |
| Shares Out | 38.56M |
| EPS (ttm) | -3.64 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 237,725 |
| Open | 3.99 |
| Previous Close | 4.00 |
| Day's Range | 3.84 - 4.15 |
| 52-Week Range | 2.06 - 23.84 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 22.19 (+453.4%) |
| Earnings Date | Aug 15, 2022 |
About ANNX
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with ... [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for ANNX stock is "Buy." The 12-month stock price forecast is 22.19, which is an increase of 453.37% from the latest price.
News
Annexon Touts Final Huntington's Trial Data Confirming No New Safety Issues
Annexon Inc (NASDAQ: ANNX) shared final data from the Phase 2 trial for ANX005 in patients with or at risk for Huntington's disease, which causes a progressive breakdown of nerve cells in the brain. Th...
Annexon Biosciences Reports Phase 2 Clinical Trial Results Demonstrating Upstream Classical Complement Inhibition Ass...
ANX005 Demonstrated Full C1q Target Inhibition and Was Generally Well-Tolerated
Annexon Biosciences to Present at the 2022 Jefferies Healthcare Conference
BRISBANE, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical co...
Annexon Biosciences to Present Data Highlighting Novel Approach to Treating Complement-Driven Diseases at Upcoming Me...
BRISBANE, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical co...
Annexon Biosciences Highlights Portfolio Progress and Key Anticipated Milestones, and Reports First Quarter 2022 Fina...
Pioneering Upstream Complement-Targeted Platform with Broad Portfolio of Five Differentiated Product Candidates
Annexon Biosciences to Participate in Upcoming May Investor Conferences
BRISBANE, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical com...
What Are Penny Stocks? What You Need to Know and 3 to Watch
Check these three penny stocks out for your watchlist The post What Are Penny Stocks? What You Need to Know and 3 to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStoc...
Annexon Biosciences Completes Enrollment in ARCHER Phase 2 Trial of Novel C1q Inhibitor, ANX007, in Patients with Geo...
Topline efficacy and safety data expected in first half of 2023 Topline efficacy and safety data expected in first half of 2023
Annexon Biosciences to Participate in the 21st Annual Needham Virtual Healthcare Conference
CAMBRIDGE, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical c...
Annexon Biosciences to Present Preclinical Data Supporting Complement Inhibitor Programs for the Treatment of Guillai...
BRISBANE, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with...
Annexon Biosciences Announces Program Highlights and Reports Fourth Quarter and Full Year 2021 Financial Results
Multiple Value-Creating Catalysts Across Complement-Targeted Portfolio Anticipated Through 2023
Annexon Biosciences to Participate in the Cowen 42nd Annual Healthcare Conference
BRISBANE, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical co...
Annexon Biosciences Appoints Bettina M. Cockroft, M.D.
BRISBANE, Calif., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with ...
Why Annexon Biosciences Stock Plummeted 34% Today
Investors were unimpressed by the biotech's latest clinical update.
Annexon's Interim Mid-Stage Results On Huntington's Disease Candidate Fails To Cheer
Annexon Inc (NASDAQ: ANNX) posted interim data from its ongoing Phase 2 trial of ANX005 in patients with Huntington's disease (HD) who completed the 24-week treatment period. Annexon is developing ANX0...
Annexon Biosciences Reports Promising Interim Phase 2 Data Showing Improvement in Clinical Measures with ANX005 in Hu...
ANX005 Has Been Generally Well-Tolerated and Has Shown Full Target Engagement of C1q in the CSF
Annexon Biosciences to Present at the 40th Annual J.P. Morgan Healthcare Conference
BRISBANE, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical co...
Annexon Biosciences Announces Clinical and Preclinical Data Highlighting Potential of Complement-Targeting Programs a...
BRISBANE, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical co...
Annexon Biosciences Announces Business and Program Highlights and Reports Third Quarter 2021 Financial Results
$271 Million Cash and Investments at End of Third Quarter 2021 Supports Operating Runway into 2024, Including Several Key Clinical Milestones across the Portfolio $271 Million Cash and Investments at En...
Annexon Biosciences Further Strengthens Its Executive Leadership Team With Appointment of Ted Yednock, Ph.D., to Chie...
– Dr. Ted Yednock's appointment enhances Annexon's commitment to scientific innovation and pursuit of future programs –
Annexon Biosciences to Participate in 2021 Cantor Virtual Global Healthcare Conference
CAMBRIDGE, Mass., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with...
Annexon Biosciences to Highlight Neurodegeneration Franchise in Upcoming Virtual C1q Series R&D Event
CAMBRIDGE, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with...
Annexon Biosciences Reports Second Quarter 2021 Financial Results and Provides Mid-Year Business Update
– Recently expanded Autoimmune franchise with advancement of third clinical candidate, ANX009, and strategically expanded into additional autoantibody-driven diseases –
Annexon Broadens Autoimmune Franchise with Advancement of Third Anti-C1q Product Candidate and Strategic Expansion in...
Advancing subcutaneous ANX009 candidate into Phase 1b program in Lupus Nephritis
Annexon to Present at the Raymond James Human Health Innovation Conference
SOUTH SAN FRANCISCO, Calif., June 16, 2021 (GLOBE NEWSWIRE) -- Today, Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing a pipeline of novel therapies for ...